Pay in 4 interest-free payments of $7.03 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
PMID 9465822
showed that MCF-7 breast cancer cells constitutively overexpressing CPT1C displayed an increased FAO-dependent ATP production, and resistance to glucose deprivation or hypoxia 43
The SURPASS trial series consistently showed that side effects are dose-dependent, meaning the starting dose of 2.5 mg weekly is intentionally low to minimize early discomfort before escalation
These are then converted to acylcarnitines by Carnitine Palmitoyl Transferase 1 (CPT 1), which is located in the outer mitochondrial membrane
Week 48 What you may notice: Measurable reduction in belly fat
US$ 28.27
US$ 27.10
US$ 22.95
US$ 29.42
